3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Stomach Neoplasms
34
Carcinoma, Hepatocellular
33
Carcinoma, Non-Small-Cell Lung
23
Colorectal Neoplasms
16
Esophageal Squamous Cell Carcinoma
12
Lung Neoplasms
9
Rectal Neoplasms
8
Nasopharyngeal Carcinoma
8
Esophageal Neoplasms
6
Cholangiocarcinoma
6
Squamous Cell Carcinoma of Head and Neck
5
Neoplasm Metastasis
5
Uterine Cervical Neoplasms
4
Triple Negative Breast Neoplasms
4
Small Cell Lung Carcinoma
4
Pancreatic Neoplasms
4
Neoplasms
4
Colonic Neoplasms
4
Carcinoma, Renal Cell
4
Lymphoma, Large B-Cell, Diffuse
3
Lymphoma, Extranodal NK-T-Cell
3
Carcinoma
3
Breast Neoplasms
3
Spinocerebellar Degenerations
2
Sarcoma
2
Recurrence
2
Nonsquamous Non-Small Cell Lung Cancer
2
Neuroendocrine Tumors
2
Lymphoma, T-Cell, Peripheral
2
Locally Advanced Rectal Cancer
2
Interventions
Oxaliplatin
26
Gemcitabine
22
Fluorouracil
17
Capecitabine
16
Leucovorin
15
pembrolizumab
14
Docetaxel
14
Cisplatin
13
Bevacizumab
12
Radiotherapy
8
Paclitaxel
8
Irinotecan
8
Trastuzumab
7
Pemetrexed
6
Carboplatin
6
130-nm albumin-bound paclitaxel
6
durvalumab
5
cemiplimab
5
Erlotinib Hydrochloride
5
Sunitinib
4
Ramucirumab
4
Metformin
4
Gefitinib
4
trastuzumab deruxtecan
3
tislelizumab
3
cabozantinib
3
atezolizumab
3
Taxes
3
Sorafenib
3
Panitumumab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Adenocarcinoma
×
sintilimab
×
Clear all
NCT05161572
2025-06-18
NeoRacing
Fudan University
Phase 2
Terminated
6 enrolled